semaglutide and vision loss Injectable weight drugs linked to rare loss Understanding the Ozempic-NAION Link: Key

The high costs present significant reimbursement issues, especially when healthcare systems around the world are facing budget pressures due to increasing use of GLP-1 agonists worldwide, where global spending on this therapeutic area is projected to exceed USD 42 billion per year in 2025

Clinical trials have shown tirzepatide to induce even greater weight loss, with patients achieving an average body weight reduction of 20.2% [1]

229 The most often used backbone modification method is PS modification, where the oxygen atom is replaced by sulfur

Skin & Collagen Health

Patients who need a lower-cost option may begin with oral medications and transition to GLP-1 therapy later if financially feasible